Cintas Boosts Annual Outlook On Solid Q2 Earnings Beat

Cintas Corporation (NASDAQ:CTAS) reported second-quarter FY23 sales growth of 13% year-on-year to $2.17 billion, beating the consensus of $2.13 billion. Organic…
  • Cintas Corporation (NASDAQ:CTAS) reported second-quarter FY23 sales growth of 13% year-on-year to $2.17 billion, beating the consensus of $2.13 billion.
  • Organic revenue growth rate was 12.8% for the quarter.
  • Gross margin expanded by 100 basis points Y/Y to 47% in the quarter.
  • Selling and administrative expenses were $577.5 million. Operating income increased 16.7% to $444.9 million, while the operating margin expanded by 70 basis points to 20.5%.
  • EPS of $3.12 beat the analyst consensus of $3.03.
  • The company held $89.8 million in cash and equivalents as of November 30, 2022. Net cash provided by operations for six months totaled $619.1 million, with a free cash flow of $472.7 million.
  • Outlook: Cintas raised its annual revenue expectations from $8.58 billion – $8.67 billion to $8.67 billion – $8.75 billion, above the consensus of $8.63 billion.
  • The company boosted the FY23 EPS outlook from $12.30 – $12.65 to $12.50 – $12.80 versus the consensus of $12.58.
  • Price Action: CTAS shares are trading higher by 2.39% at $454.55 on the last check Wednesday.
Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Calquence Tablet Formulation Approved in the US Across Current Indications

AstraZeneca's new tablet formulation of Calquence (acalabrutinib) has been approved in the US for all current indications, including adult patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and for patients with relapsed or refractory mantle cell lymphoma (MCL), which is approved under accelerated approval based on overall response rate.

AZN